3 results
1. Overall survival (primary efficacy endpoint)2a. Efficacy: progression-free survival (PFS), overall response rate (ORR = CR + PR), and a clincal benefit rate (CBR) will be evaluated as CR + PR + SD for at least 3 months.2b. Safety: adverse events…
Primary: - To evaluate the efficacy of 2 dose quantities of lasmiditan on migraine headache pain freedom compared to placebo - To evaluate the consistency of response to 2 dose quantities of lasmiditan compared to placeboSecondary: - To evaluate the…
Primary- To test the hypothesis that lasmiditan high dose is superior to placebo in the acute treatment of a migraine attack in pediatric patients >=6 to <18 years of ageKey Secondary- To test the hypothesis that lasmiditan medium dose…